AbbVie Says Q1 2024 Adj Diluted Earnings Per Share Guidance Range, Including Impact Of Q1 2024 Acquired IPR&D And Milestones Expense, Is $2.18-$2.22; Reported GAAP Earnings For Q1 Of 2024 Are Expected To Include Acquired IPR&D And Milestones Expense Of $164M On A Pre-tax Basis
Portfolio Pulse from Benzinga Newsdesk
AbbVie projects its Q1 2024 adjusted diluted EPS to be in the range of $2.18-$2.22, accounting for acquired IPR&D and milestones expense of $164M on a pre-tax basis. The company's reported GAAP earnings for Q1 2024 will include these expenses, as disclosed in an SEC filing.
April 03, 2024 | 8:27 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AbbVie anticipates its Q1 2024 adjusted diluted EPS to fall between $2.18 and $2.22, factoring in a significant pre-tax expense of $164M for acquired IPR&D and milestones.
The guidance provided by AbbVie includes significant expenses related to acquired IPR&D and milestones, which are factored into the adjusted EPS range. This transparency in financial forecasting could be seen as a positive signal to investors, indicating management's confidence in the company's financial health and strategic acquisitions. However, the impact of the $164M expense on the overall financial performance could be a concern, making the short-term stock price reaction neutral.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100